Jochen Brumm

3.1k total citations · 1 hit paper
29 papers, 2.1k citations indexed

About

Jochen Brumm is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Jochen Brumm has authored 29 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 7 papers in Immunology and 5 papers in Oncology. Recurrent topics in Jochen Brumm's work include Biosimilars and Bioanalytical Methods (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Air Quality and Health Impacts (3 papers). Jochen Brumm is often cited by papers focused on Biosimilars and Bioanalytical Methods (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Air Quality and Health Impacts (3 papers). Jochen Brumm collaborates with scholars based in United States, Canada and Switzerland. Jochen Brumm's co-authors include Hardi Mundl, Markus Abt, Ingar Holme, John J.V. McMurray, Christie M. Ballantyne, Anders Olsson, Lawrence A. Leiter, Philip J. Barter, David Kallend and Bernard Chaitman and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Jochen Brumm

25 papers receiving 2.1k citations

Hit Papers

Effects of Dalcetrapib in Patients with a Recent Acute Co... 2012 2026 2016 2021 2012 400 800 1.2k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jochen Brumm United States 12 1.1k 829 419 379 317 29 2.1k
Monica Gomaraschi Italy 28 933 0.9× 798 1.0× 581 1.4× 430 1.1× 359 1.1× 64 2.3k
Megan F. Burke United States 7 915 0.8× 812 1.0× 327 0.8× 350 0.9× 301 0.9× 9 1.7k
Günther Silbernagel Austria 30 1.0k 1.0× 804 1.0× 491 1.2× 563 1.5× 181 0.6× 95 2.7k
Chiara Macchi Italy 28 1.1k 1.0× 489 0.6× 583 1.4× 312 0.8× 264 0.8× 83 2.4k
Thimoteus Speer Germany 27 534 0.5× 374 0.5× 640 1.5× 497 1.3× 217 0.7× 80 2.5k
Damiano Baldassarre Italy 28 890 0.8× 687 0.8× 319 0.8× 1.5k 4.0× 262 0.8× 95 3.1k
Greg Hough United States 26 1.7k 1.6× 1.3k 1.5× 982 2.3× 415 1.1× 678 2.1× 41 3.7k
Kashif Jafri United States 10 968 0.9× 862 1.0× 308 0.7× 374 1.0× 300 0.9× 13 1.9k
Bo Liang China 25 399 0.4× 267 0.3× 490 1.2× 250 0.7× 173 0.5× 124 1.9k
Ana Cenarro Spain 32 1.3k 1.2× 837 1.0× 847 2.0× 464 1.2× 564 1.8× 154 2.9k

Countries citing papers authored by Jochen Brumm

Since Specialization
Citations

This map shows the geographic impact of Jochen Brumm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochen Brumm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochen Brumm more than expected).

Fields of papers citing papers by Jochen Brumm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochen Brumm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochen Brumm. The network helps show where Jochen Brumm may publish in the future.

Co-authorship network of co-authors of Jochen Brumm

This figure shows the co-authorship network connecting the top 25 collaborators of Jochen Brumm. A scholar is included among the top collaborators of Jochen Brumm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jochen Brumm. Jochen Brumm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ruppel, Jane, et al.. (2025). Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment. SHILAP Revista de lepidopterología. 11(1).
2.
Tsai, Wen‐Ting K., Yinyin Li, Zhaojun Yin, et al.. (2024). Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG 1 antibodies. mAbs. 16(1). 2362789–2362789. 7 indexed citations
3.
Nijem, Ihsan, R. L. Elliott, Jochen Brumm, et al.. (2024). Cross validation of pharmacokinetic bioanalytical methods: Experimental and statistical design. Journal of Pharmaceutical and Biomedical Analysis. 252. 116485–116485. 2 indexed citations
4.
Cao, Dachuang, et al.. (2024). 8366 Weight Reduction is Associated with Improved Quality of Life in Patients in SURMOUNT-3. Journal of the Endocrine Society. 8(Supplement_1). 1 indexed citations
5.
Adedeji, Adeyemi O., Rachel N. Andrews, Paula Katavolos, et al.. (2023). Analysis of cellularity in H&E-stained rat bone marrow tissue via deep learning. Journal of Pathology Informatics. 14. 100333–100333. 1 indexed citations
6.
Rubino, Domenica, Sue D. Pedersen, Lisa Connery, et al.. (2023). TOLERABILITY AND WEIGHT REDUCTION OF TIRZEPATIDE IN ADULTS WITH OBESITY OR OVERWEIGHT. Canadian Journal of Diabetes. 47(7). S136–S136. 1 indexed citations
7.
Santagostino, Sara Francesca, et al.. (2022). Assessment of Skin Toxicity in an in Vitro Reconstituted Human Epidermis Model Using Deep Learning. American Journal Of Pathology. 192(4). 687–700. 11 indexed citations
8.
Tran, Peter, Justin Low, Manda Wong, et al.. (2022). Introducing Dendritic Cell Antibody Internalization as an Immunogenicity Risk Assessment Tool. Bioanalysis. 14(10). 703–713. 10 indexed citations
9.
Cohen, Sivan, Shan Chung, Christoph Spiess, et al.. (2021). An integrated approach for characterizing immunogenic responses toward a bispecific antibody. mAbs. 13(1). 1944017–1944017. 16 indexed citations
10.
Cohen, Sivan, et al.. (2021). Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells. mAbs. 13(1). 1898831–1898831. 22 indexed citations
11.
Fullerton, Aaron, Jochen Brumm, Tomomi Kiyota, et al.. (2020). In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk. Archives of Toxicology. 94(9). 3185–3200. 6 indexed citations
12.
Lambert, Nathalie, et al.. (2016). Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. Diabetes Obesity and Metabolism. 19(4). 537–544. 4 indexed citations
13.
Cai, Fang, David F. Choy, Jochen Brumm, et al.. (2015). LATE-BREAKING ABSTRACT: Serum IL-13 is a peripheral biomarker for Type 2 asthma. PA4364–PA4364.
14.
Schwartz, Gregory G., Anders Olsson, Markus Abt, et al.. (2012). Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine. 367(22). 2089–2099. 1465 indexed citations breakdown →
15.
Sui, Shannan J. Ho, Daniel J. Erasmus, Jochen Brumm, et al.. (2008). Dynamics of the yeast transcriptome during wine fermentation reveals a novel fermentation stress response. FEMS Yeast Research. 8(1). 35–52. 138 indexed citations
16.
Podowski, Raf M., Dimas Yusuf, Jochen Brumm, et al.. (2008). Gene Characterization Index: Assessing the Depth of Gene Annotation. PLoS ONE. 3(1). e1440–e1440. 10 indexed citations
17.
Lam, Karen, Jochen Brumm, Matthew Saunders, et al.. (2008). Global Analysis of Yeast Endosomal Transport Identifies the Vps55/68 Sorting Complex. Molecular Biology of the Cell. 19(4). 1282–1294. 25 indexed citations
19.
Huang, Yong, Sohrab P. Shah, Jonathan Lim, et al.. (2005). Ulysses - an application for the projection of molecular interactions across species. Genome biology. 6(12). R106–R106. 21 indexed citations
20.
Bräuer, Michael, Jochen Brumm, Sverre Vedal, & A. John Petkau. (2002). Exposure Misclassification and Threshold Concentrations in Time Series Analyses of Air Pollution Health Effects. Risk Analysis. 22(6). 1183–1193. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026